Grant: TITAN PHARMACEUTICALS, INC.
Primary Recipient
TITAN PHARMACEUTICALS, INC.
Amount
$7,586,848.00
Award Date
9/30/2009
Administering Agency
Health and Human Services, Department of / National Institutes of Health
CDFA Number
93.701
CDFA Program Title
Trans-NIH Recovery Act Research Support
Description
Project Title: A Six-Month, RCT of Probuphine Safety and Efficacy in Opioid Addiction. We are conducting a six-month, randomized, placebo and active-controlled, multicenter clinical trial of Probuphine in patients with opioid dependence for the purpose
Recipients Connected to Award
Recipient | Role | Amount |
---|---|---|
TITAN PHARMACEUTICALS, INC. | Primary recipient | $4,796,227.54 |
UNIVERSITY OF CINCINNATI | Sub-recipient | $589,657.00 |
NORTH COUNTY CLINICAL RESEARCH, INC. | Sub-recipient | $454,813.46 |
SYNERGY CLINICAL RESEARCH CENTER | Sub-recipient | $282,915.56 |
SCIENTIFIC CLINICAL RESEARCH, INC. | Sub-recipient | $201,203.79 |
UNIVERSITY OF CALIFORNIA, LOS ANGELES | Sub-recipient | $191,645.46 |
FIDELITY CLINICAL RESEARCH, INC. | Sub-recipient | $178,369.00 |
Psychcare Consultants Research | Sub-recipient | $162,647.56 |
VIJAPURA, AMIT MD | Sub-recipient | $156,766.32 |
DUKE UNIVERSITY | Sub-recipient | $123,468.20 |
JOHNS HOPKINS UNIVERSITY, THE | Sub-recipient | $114,027.00 |
STANLEY STREET TREATMENT AND RESOURCES, INC. | Sub-recipient | $82,547.19 |
The Narrows Institute For Biomedical Research Inc | Sub-recipient | $63,509.50 |
ST LUKE'S-ROOSEVELT HOSPITAL CENTER | Sub-recipient | $59,167.00 |
PROVIDENCE HEALTH & SERVICES-WASHINGTON | Sub-recipient | $51,283.50 |
OPERATION PAR, INC. | Sub-recipient | $50,100.36 |
PRECISE RESEARCH CENTERS | Sub-recipient | $26,999.56 |
NORTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION, INC. | Sub-recipient | $1,500.00 |
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | Sub-recipient | $0.00 |
Vendors Connected to Award
Vendor | Role | Amount |
---|---|---|
Catalent Pharma Solutions | Primary vendor | $66,024.54 |
Catalent Pharma Solutions | Primary vendor | $44,841.62 |
Catalent Pharma Solutions | Primary vendor | $12,955.17 |
Covance Central Laboratory Services | Primary vendor | $144,058.23 |
Covance Central Laboratory Services | Primary vendor | $25,504.35 |
PPD, Inc | Primary vendor | $27,710.17 |
PPD, Inc | Primary vendor | $74,308.00 |
PPD, Inc | Primary vendor | $153,637.13 |
PPD, Inc | Primary vendor | $69,107.52 |
Catalent Pharma Solutions | Primary vendor | $70,996.89 |
Covance Central Laboratory Services | Primary vendor | $61,880.34 |
Covance Central Laboratory Services | Primary vendor | $102,403.27 |
Covance Central Laboratory Services | Primary vendor | $191,439.98 |
PPD, Inc | Primary vendor | $72,390.66 |
PPD, Inc | Primary vendor | $28,153.14 |
PPD, Inc | Primary vendor | $102,628.58 |
PPD, Inc | Primary vendor | $120,843.81 |
Catalent Pharma Solutions | Primary vendor | $53,584.38 |
Covance Central Laboratory Services | Primary vendor | $394,857.51 |
Covance Central Laboratory Services | Primary vendor | $362,159.28 |
PPD, Inc | Primary vendor | $188,788.13 |
PPD, Inc | Primary vendor | $198,160.46 |
PPD, Inc | Primary vendor | $195,193.50 |
Covance Central Laboratory Services | Primary vendor | $306,422.20 |
PPD, Inc | Primary vendor | $377,370.56 |
PPD, Inc | Primary vendor | $257,897.28 |
PPD, Inc | Primary vendor | $307,332.81 |